Table 2.
Result of antibody testing during the three surveys in 5 cities of Hiroshima prefecture
|
Ortho Anti-S Total (IgG,
IgM, IgA)* |
Ortho Anti-S IgG** | Roche anti-N IgG*** | Abbott anti-N IgG**** |
First round
(N = 3,025) |
Second round
(N = 2,396) |
Third round
(N = 2,351) |
|
| At least two positive tests from two different immunoassays | Positive (+) | Positive (+) | Positive (+) | Positive (+) | 1 | 1 | 5 |
| Positive (+) | Positive (+) | Negative (−) | Positive (+) | 0 | 0 | 1 | |
| Positive (+) | Positive (+) | Negative (−) | Negative (−) | 0 | 1 | 1 | |
|
| |||||||
| Negative tests on all immunoassays or only one immunoassay positive | Positive (+) | Negative (−) | Negative (−) | Negative (−) | 1 | 4 | 2 |
| Negative (−) | Positive (+) | Negative (−) | Negative (−) | 7 | 7 | 7 | |
| Negative (−) | Negative (−) | Positive (+) | Negative (−) | 3 | 5 | 8 | |
| Negative (−) | Negative (−) | Negative (−) | Positive (+) | 8 | 4 | 6 | |
| Negative (−) | Negative (−) | Negative (−) | Negative (−) | 3,005 | 2,374 | 2,321 | |
Antibody positivity was defined as at least two positive results from the four immunological tests.
*Total antibody (IgG, IgM, IgA) to SARS-CoV-2 Spike protein detected by chemiluminescent enzyme immunoassay (CLEIA) using VITROS Anti-SARS-CoV-2 Total (Ortho Clinical Diagnostics, USA)
**Immunoglobulin G (IgG) to SARS-CoV-2 Spike protein detected by chemiluminescent immunoassay (CLEIA) using VITROS Anti-SARS-CoV-2 IgG (Ortho Clinical Diagnostics, USA)
***IgG to SARS-CoV-2 nucleocapsid protein detected electrochemiluminescence immunoassay (ECLIA) using ELECSYS Anti-SARS-CoV-2 (incl. IgG) (Roche Diagnostics, Swiss)
****IgG to SARS-CoV-2 nucleocapsid protein detected by chemiluminescent immunoassay (CLIA) using ARCHITECT SARS-CoV-2 IgG (Abbott Laboratories, USA)